Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Aldeyra Therapeu (NQ: ALDX ) 3.395 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jun 20, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 3.395 Bid (Size) 3.290 (5) Ask (Size) 3.400 (8) Prev. Close 3.395 Today's Range 3.395 - 3.395 52wk Range 1.460 - 8.940 Shares Outstanding 58,576,350 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable June 20, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease June 13, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Performance YTD -4.10% -4.10% 1 Month -13.83% -13.83% 3 Month +16.67% +16.67% 6 Month +1.34% +1.34% 1 Year -56.02% -56.02% More News Read More Aldeyra Therapeutics to Host Investor Roundtable Q&A June 12, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference May 29, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease May 08, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire ALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024 May 03, 2024 Via InvestorPlace Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day April 25, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024 April 18, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying April 04, 2024 Via Benzinga Topics Stocks Exposures US Equities Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease March 28, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire 12 Health Care Stocks Moving In Tuesday's After-Market Session March 05, 2024 Via Benzinga ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm February 09, 2024 From Bragar Eagel & Squire Via GlobeNewswire Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference February 06, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases January 04, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Positive News For Skin Health: Aldeyra Therapeutics' ADX-629 Achieves Key Milestones in Atopic Dermatitis Study December 19, 2023 Via Benzinga Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis December 19, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis December 18, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire 3 Stocks at the Forefront of Personalized Medicine Trend December 05, 2023 Via InvestorPlace FDA Rejects Aldeyra Therapeutics' Dry Eye Disease Candidate, Asks For Additional Study November 28, 2023 Via Benzinga Exposures Product Safety Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease November 27, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire 12 Health Care Stocks Moving In Wednesday's Intraday Session November 01, 2023 Via Benzinga What's Going On With Aldeyra Therapeutics Stock? November 01, 2023 Via Benzinga Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session November 01, 2023 Via Benzinga Aldeyra Therapeutics Inc. (NASDAQ: ALDX) is One of Wednesday Morning’s Most Active Stocks November 01, 2023 Via Investor Brand Network Why Are Stocks Up Today? November 01, 2023 Via InvestorPlace Topics Economy Exposures Interest Rates Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
